Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020
Cash flows used in operating activities:
Net loss	$ (37,024)	$ (25,170)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	8,454	7,407
Operating lease right-of-use asset	712	61
Depreciation	63	71
Amortization of premium on marketable debt securities	1,280
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(605)	1,107
Other Assets, non-current	213	(42)
Accounts payable	14	1,197
Accrued expenses	5	(1,236)
Operating lease liabilities	(707)	(36)
Net cash used in operating activities	(27,595)	(16,641)
Cash flows (used in)/provided by investing activities:
Cash and restricted cash acquired in connection with the reverse merger with ArTara Therapeutics, Inc.		3,719
Purchase of marketable debt securities, available-for-sale	(115,959)
Proceeds from maturity of marketable debt securities, available-for-sale	2,600
Proceeds from redemption of marketable debt securities, available-for-sale	13,828
Purchase of property and equipment	(552)	(373)
Net cash (used in)/provided by investing activities	(100,083)	3,346
Cash flows (used in)/provided by financing activities:
Proceeds from - ArTara Private Placement, net of offering costs		1,867
Proceeds from - Common Stock in Proteon Private Placement, net of offering costs		12,413
Proceeds from - Series 1 Convertible Preferred Stock in Proteon Private Placement, net of offering costs		25,319
Proceeds from September Series 1 Convertible Preferred, net of offering costs		66,284
Proceeds from September Common Stock, net of offering costs		73,571
Repayments under short-term debt		(1,298)
Proceeds from the exercise of stock options		530
Repurchase of shares in connection with settlement of RSUs	(228)
Net cash (used in)/provided by financing activities	(228)	178,686
Net (decrease)/increase in cash and cash equivalents and restricted cash	(127,906)	165,391
Cash and cash equivalents and restricted cash - beginning of year	169,393	564
Cash and cash equivalents and restricted cash - end of period	41,487	165,955
Cash paid for:
Interest		26
Income Taxes
Non-cash investing and financing activities:
Deferred offering costs recognized that were previously recorded in accrued expenses		122
Purchase of insurance agreement with notes payable		1,669
Common stock issued in connection with the reverse merger with ArTara Therapeutics, Inc.		$ 34,533